{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T16:22:15Z","timestamp":1792858935993,"version":"4.5.0"},"reference-count":93,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40257-025-00940-0","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T09:58:08Z","timestamp":1743847088000},"page":"487-497","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comprehensive and Updated Algorithm of Hidradenitis Suppurativa Management from the Experts"],"prefix":"10.1007","volume":"26","author":[{"given":"Caitlyn B.","family":"Dagenet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina H.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7510-9428","authenticated-orcid":false,"given":"Vivian Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,3]]},"reference":[{"issue":"1","key":"940_CR1","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaad.2019.02.068","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91\u2013101.","journal-title":"J Am Acad Dermatol"},{"key":"940_CR2","volume-title":"A comprehensive guide to hidradenitis suppurativa","year":"2022","unstructured":"Shi VY, Hsiao JL, Lowes M, Hamzavi IH, editors. A comprehensive guide to hidradenitis suppurativa. Philadelphia: Elsevier; 2022."},{"issue":"7","key":"940_CR3","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s13555-023-00935-x","volume":"13","author":"A Hunt","year":"2023","unstructured":"Hunt A, Qian V, Olds H, Daveluy S. The current clinical trial landscape for hidradenitis suppurativa: a narrative review. Dermatol Ther (Heidelb). 2023;13(7):1391\u2013407.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10","key":"940_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.36849\/JDD.7339","volume":"22","author":"L Westerkam","year":"2023","unstructured":"Westerkam L, Sayed C. A review of the current landscape of hidradenitis suppurativa treatment development. J Drugs Dermatol. 2023;22(10):1021\u20136.","journal-title":"J Drugs Dermatol"},{"key":"940_CR5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20472","author":"CC Zouboulis","year":"2024","unstructured":"Zouboulis CC, Bechara FG, Benhadou F, Bettoli V, Bukvi\u0107 Mokos Z, Del Marmol V, et al. European S2k guidelines for hidradenitis suppurativa\/acne inversa part 2: treatment. J Eur Acad Dermatol Venereol. 2024. https:\/\/doi.org\/10.1111\/jdv.20472.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"940_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jaad.2019.02.067","volume":"81","author":"A Alikhan","year":"2019","unstructured":"Alikhan A, Sayed C, Alavi A. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian Hidradenitis Suppurativa Foundations: part I: diagnosis, evaluation, and the use of complementary and procedural management. J Am Acad Dermatol. 2019;81(1):76\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"940_CR7","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1097\/AOG.0000000000004321","volume":"137","author":"CJ Sayed","year":"2021","unstructured":"Sayed CJ, Hsiao JL, Okun MM, Hidradenitis Suppurativa Foundation Women\u2019s Health Subcommittee. Clinical epidemiology and management of hidradenitis suppurativa. Obstet Gynecol. 2021;137(4):731\u201346.","journal-title":"Obstet Gynecol"},{"issue":"9","key":"940_CR8","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/j.1468-3083.2009.03356.x","volume":"23","author":"J Revuz","year":"2009","unstructured":"Revuz J. Hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2009;23(9):985\u201398.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"940_CR9","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1111\/jdv.12966","volume":"29","author":"CC Zouboulis","year":"2015","unstructured":"Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juh\u00e1sz I, et al. European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619\u201344.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"940_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.det.2015.08.009","volume":"34","author":"JE Revuz","year":"2016","unstructured":"Revuz JE, Jemec GBE. Diagnosing hidradenitis suppurativa. Dermatol Clin. 2016;34(1):1\u20135.","journal-title":"Dermatol Clin"},{"issue":"4","key":"940_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamadermatol.2020.5467","volume":"157","author":"JW Frew","year":"2021","unstructured":"Frew JW, Lowes MA, Goldfarb N. Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary. JAMA Dermatol. 2021;157(4):449\u201355.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"940_CR12","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1159\/000507348","volume":"236","author":"M Daxhelet","year":"2020","unstructured":"Daxhelet M, Suppa M, White J, Benhadou F, Thorlacius LR, Jemec GBE, et al. Proposed definitions of typical lesions in hidradenitis suppurativa. Dermatology. 2020;236(5):431\u20138.","journal-title":"Dermatology"},{"issue":"2","key":"940_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000443878","volume":"232","author":"D Lipsker","year":"2016","unstructured":"Lipsker D, Severac F, Freysz M, Sauleau E, Boer J, Emtestam L, et al. The ABC of Hidradenitis suppurativa: a validated glossary on how to name lesions. Dermatology. 2016;232(2):137\u201342.","journal-title":"Dermatology"},{"key":"940_CR14","unstructured":"Hurley H, Roenigk RK, Roenigk HH. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. Dermatol Surg. 1989:729\u2013739."},{"key":"940_CR15","doi-asserted-by":"publisher","first-page":"1145152","DOI":"10.3389\/fmed.2023.1145152","volume":"10","author":"M Daoud","year":"2023","unstructured":"Daoud M, Suppa M, Benhadou F, Daxhelet M, Njimi H, White J, et al. Overview and comparison of the clinical scores in hidradenitis suppurativa: a real-life clinical data. Front Med (Lausanne). 2023;10:1145152.","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"940_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s13555-023-01085-w","volume":"14","author":"AB Kimball","year":"2024","unstructured":"Kimball AB, Kirby J, Ingram JR, Tran T, Pansar I, Ciaravino V, et al. Burden of hidradenitis suppurativa: a systematic literature review of patient reported outcomes. Dermatol Ther (Heidelb). 2024;14(1):83\u201398.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"940_CR17","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1177\/1203475416677721","volume":"21","author":"M Sisic","year":"2017","unstructured":"Sisic M, Kirby JS, Boyal S, Plant L, McLellan C, Tan J. Development of a quality-of-life measure for hidradenitis suppurativa. J Cutan Med Surg. 2017;21(2):152\u20135.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"940_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1177\/1203475420930222","volume":"24","author":"LAV Orenstein","year":"2020","unstructured":"Orenstein LAV, Amah A, Shaw FM, Zhang C, Swerlick RA, Chen SC. Validation of the three-item Skindex-Mini among hidradenitis suppurativa patients with diverse racial backgrounds. J Cutan Med Surg. 2020;24(5):457\u201360.","journal-title":"J Cutan Med Surg"},{"issue":"5","key":"940_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1016\/j.jaad.2021.01.059","volume":"86","author":"A Garg","year":"2022","unstructured":"Garg A, Malviya N, Strunk A. Comorbidity screening in hidradenitis suppurativa: evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"940_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/ijd.15111","volume":"60","author":"M Shah","year":"2021","unstructured":"Shah M, Sachdeva M, Melendez-Gonzalez M, Piguet V, Sayed C. Hidradenitis suppurativa and chromosomal abnormalities: a case report and systematic review of the literature. Int J Dermatol. 2021;60(3):261\u201371.","journal-title":"Int J Dermatol"},{"issue":"4","key":"940_CR21","first-page":"176","volume":"108","author":"T Shih","year":"2021","unstructured":"Shih T, Shi V, Hsiao JL. Treatment stacking: optimizing therapeutic regimens for hidradenitis suppurativa. Cutis. 2021;108(4):176\u20138.","journal-title":"Cutis"},{"issue":"6","key":"940_CR22","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/S0190-9622(98)70272-5","volume":"39","author":"GB Jemec","year":"1998","unstructured":"Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 1998;39(6):971\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"940_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/j.1365-4362.1983.tb02150.x","volume":"22","author":"OJ Clemmensen","year":"1983","unstructured":"Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol. 1983;22(5):325\u20138.","journal-title":"Int J Dermatol"},{"issue":"6","key":"940_CR24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1159\/000531926","volume":"9","author":"A Katoulis","year":"2023","unstructured":"Katoulis A, Efthymiou O, Liakou A, Pappa G, Kanelleas A, Koumaki D, et al. Resorcinol 10% as a promising therapeutic option for mild hidradenitis suppurativa: a prospective, randomized, open study. Skin Appendage Disord. 2023;9(6):438\u201343.","journal-title":"Skin Appendage Disord."},{"issue":"4","key":"940_CR25","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1159\/000530758","volume":"239","author":"P Aarts","year":"2023","unstructured":"Aarts P, Reeves JL, Ardon CB, Zee HH, Prens EP. Clindamycin-benzoyl peroxide gel compared with clindamycin lotion for hidradenitis suppurativa: a randomized controlled assessor-blinded intra-patient pilot study. Dermatology. 2023;239(4):670\u20134.","journal-title":"Dermatology"},{"issue":"1","key":"940_CR26","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jaad.2023.08.064","volume":"90","author":"A Hargis","year":"2024","unstructured":"Hargis A, Yaghi M, Maskan Bermudez N, Lev-Tov H. Clascoterone in the treatment of mild hidradenitis suppurativa. J Am Acad Dermatol. 2024;90(1):142\u20134.","journal-title":"J Am Acad Dermatol"},{"key":"940_CR27","unstructured":"Porter MJ, et al. Efficacy and safety of ruxolitinib cream in patients with hidradenitis suppurativa (Hurley Stage I and II): results from a randomised, double-blind, vehicle-controlled phase 2 study. LB2, 2024 AAD Annual Meeting, 8\u201312 March, San Diego, USA."},{"issue":"6","key":"940_CR28","doi-asserted-by":"publisher","first-page":"515","DOI":"10.5021\/ad.2021.33.6.515","volume":"33","author":"JH An","year":"2021","unstructured":"An JH, Moon SJ, Shin JU, Kim DH, Yoon MS, Lee HJ. Clindamycin mono-therapy of hidradenitis suppurativa patients: a single-center retrospective study. Ann Dermatol. 2021;33(6):515\u201321.","journal-title":"Ann Dermatol"},{"issue":"37","key":"940_CR29","first-page":"1","volume":"5","author":"R Masson","year":"2023","unstructured":"Masson R, Seivright J, Shih T. Trimethoprim\/sulfamethoxazole and cephalexin combination therapy in hidradenitis suppurativa patients: a series of 16 cases. JAAD Case Rep. 2023;5(37):1\u20134.","journal-title":"JAAD Case Rep."},{"issue":"3","key":"940_CR30","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamadermatol.2023.6201","volume":"160","author":"A Nosrati","year":"2024","unstructured":"Nosrati A, Ch\u2019en PY, Torpey ME, Shokrian N, Ball G, Benesh G, et al. Efficacy and durability of intravenous ertapenem therapy for recalcitrant hidradenitis suppurativa. JAMA Dermatol. 2024;160(3):312\u20138.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"940_CR31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1159\/000526019","volume":"239","author":"M Sanchez-Diaz","year":"2023","unstructured":"Sanchez-Diaz M, Diaz-Calvillo P, Rodriguez-Pozo J\u00c5, Arias-Santiago S, Molina-Leyva A. Effectiveness and safety of acitretin for the treatment of hidradenitis suppurativa, predictors of clinical response: a cohort study. Dermatology. 2023;239(1):52\u20139.","journal-title":"Dermatology"},{"issue":"4","key":"940_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/ced\/llad385","volume":"49","author":"CY Huang","year":"2024","unstructured":"Huang CY, Shah SA, Cochrane M, Douglas A, Yang S. Hidradenitis suppurativa disease control associated with type of hormonal contraceptive use. Clin Exp Dermatol. 2024;49(4):375\u20138.","journal-title":"Clin Exp Dermatol"},{"issue":"6665","key":"940_CR33","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1136\/bmj.298.6665.28","volume":"298","author":"AJ Stellon","year":"1989","unstructured":"Stellon AJ, Wakeling M. Hidradenitis suppurativa associated with use of oral contraceptives. BMJ. 1989;298(6665):28\u20139.","journal-title":"BMJ"},{"issue":"7","key":"940_CR34","first-page":"697","volume":"11","author":"T Montero-Vilchez","year":"2021","unstructured":"Montero-Vilchez T, Valenzuela-Amigo A, Cuenca-Barrales C, Arias-Santiago S, Leyva-Garc\u00eda A, Molina-Leyva A. The role of oral contraceptive pills in hidradenitis suppurativa: a cohort study. Life (Basel). 2021;11(7):697.","journal-title":"Life (Basel)."},{"issue":"8","key":"940_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24086969","volume":"24","author":"R Hambly","year":"2023","unstructured":"Hambly R, Kearney N, Hughes R, Fletcher JM, Kirby B. Metformin treatment of hidradenitis suppurativa: effect on metabolic parameters, inflammation, cardiovascular risk biomarkers, and immune mediators. Int J Mol Sci. 2023;24(8):6969. https:\/\/doi.org\/10.3390\/ijms24086969.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"940_CR36","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1111\/bjd.15233","volume":"177","author":"L Jennings","year":"2017","unstructured":"Jennings L, Nestor L, Molloy O, Hughes R, Moriarty B, Kirby B. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177(3):858\u20139.","journal-title":"Br J Dermatol"},{"issue":"12","key":"940_CR37","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/ijd.16892","volume":"62","author":"T Henry","year":"2023","unstructured":"Henry T, Cahn B, Haber R, Landers JT, Berger-Fleishman R, Alam M, et al. Therapeutic potential of GLP-1 agonists for hidradenitis suppurativa. Int J Dermatol. 2023;62(12):1543\u20134.","journal-title":"Int J Dermatol"},{"issue":"4","key":"940_CR38","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/bjd\/ljae216","volume":"191","author":"D Lyons","year":"2024","unstructured":"Lyons D, Louly Nathan A, Pender E, Murray G, Smith C, Kirby B, et al. Semaglutide for weight loss in people with obesity as an adjunctive treatment for hidradenitis suppurativa: its impact on disease control and quality of life. Br J Dermatol. 2024;191(4):631\u20133.","journal-title":"Br J Dermatol"},{"issue":"1","key":"940_CR39","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1159\/000503606","volume":"236","author":"CC Zouboulis","year":"2020","unstructured":"Zouboulis CC, Hansen H, Caposiena Caro RD, Damiani G, Delorme I, Pascual JC, et al. Adalimumab dose intensification in recalcitrant hidradenitis suppurativa\/acne inversa. Dermatology. 2020;236(1):25\u201330.","journal-title":"Dermatology"},{"issue":"6","key":"940_CR40","doi-asserted-by":"publisher","first-page":"615","DOI":"10.36849\/JDD.6868","volume":"22","author":"J Williams","year":"2023","unstructured":"Williams J, Guzik C, Wadhera A, Naik H. Increased doses of adalimumab are associated with clinical improvement of hidradenitis suppurativa. J Drugs Dermatol. 2023;22(6):615\u20138.","journal-title":"J Drugs Dermatol"},{"key":"940_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2147\/CCID.S449367","volume":"17","author":"F Martora","year":"2024","unstructured":"Martora F, Marasca C, Cacciapuoti S, Fariello F, Potestio L, Battista T, et al. Secukinumab in hidradenitis suppurativa patients who failed adalimumab: a 52-week real-life study. Clin Cosmet Investig Dermatol. 2024;17:159\u201366.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"940_CR42","unstructured":"Kimball AB, Zouboulis CC, Sayed C, et al. Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa: 48-week efficacy and safety from BE HEARD I & II, two phase 3, randomized, double-blind, placebo controlled, multicenter studies. 2023 American Academy of Dermatology Annual Meeting."},{"issue":"6","key":"940_CR43","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jamadermatol.2021.0220","volume":"157","author":"LL Westerkam","year":"2021","unstructured":"Westerkam LL, Tackett KJ, Sayed CJ. Comparing the effectiveness and safety associated with infliximab vs infliximab-abda therapy for patients with hidradenitis suppurativa. JAMA Dermatol. 2021;157(6):708\u201311.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"940_CR44","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.jaad.2019.09.071","volume":"82","author":"MH Ghias","year":"2020","unstructured":"Ghias MH, Johnston AD, Kutner AJ, Micheletti RG, Hosgood HD, Cohen S. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094\u2013101.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"940_CR45","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.jaad.2019.05.022","volume":"81","author":"AN Oskardmay","year":"2019","unstructured":"Oskardmay AN, Miles JA, Sayed CJ. Determining the optimal dose of infliximab for treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;81(3):702\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"940_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/rheumatology\/ket260","volume":"53","author":"M Jani","year":"2014","unstructured":"Jani M, Barton A, Warren RB, Griffiths CEM, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford). 2014;53(2):213\u201322.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"940_CR47","doi-asserted-by":"publisher","first-page":"AB42","DOI":"10.1016\/j.jaad.2023.07.172","volume":"89","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Ackerman L, Schlosser BJ, Prajapati VH, Fretzin S, Takahashi H, et al. 43799 Efficacy and safety of upadacitinib in moderate-to-severe hidradenitis suppurativa: a phase 2, randomized, placebo-controlled study. J Am Acad Dermatol. 2023;89(3):AB42.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"940_CR48","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1111\/bjd.20969","volume":"186","author":"A Alavi","year":"2022","unstructured":"Alavi A, Hamzavi I, Brown K. Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol. 2022;186(5):803\u201313.","journal-title":"Br J Dermatol"},{"issue":"3","key":"940_CR49","doi-asserted-by":"publisher","DOI":"10.1093\/omcr\/omad003","volume":"2023","author":"A Sadeghzadeh Bazargan","year":"2023","unstructured":"Sadeghzadeh Bazargan A, Pashaei A, Goodarzi A. Successful treatment of Hidradenitis Suppurativa with tofacitinib: two cases and a review of the literature. Oxf Med Case Reports. 2023;2023(3):omad003. https:\/\/doi.org\/10.1093\/omcr\/omad003.","journal-title":"Oxf Med Case Reports"},{"issue":"3","key":"940_CR50","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/bjd.21066","volume":"187","author":"SW Jiang","year":"2022","unstructured":"Jiang SW, Kwock JT, Liu B. High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. Br J Dermatol. 2022;187(3):417\u20139.","journal-title":"Br J Dermatol"},{"issue":"7","key":"940_CR51","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1093\/ced\/llad130","volume":"48","author":"N Kearney","year":"2023","unstructured":"Kearney N, Hughes R, Kirby B. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic. Clin Exp Dermatol. 2023;48(7):790\u20132.","journal-title":"Clin Exp Dermatol"},{"issue":"5","key":"940_CR52","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.jaad.2020.05.007","volume":"83","author":"JW Frew","year":"2020","unstructured":"Frew JW, Navrazhina K, Grand D, Sullivan-Whalen M, Gilleaudeau P, Garcet S, et al. The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: an open-label cohort study. J Am Acad Dermatol. 2020;83(5):1341\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"940_CR53","first-page":"9566","volume":"15","author":"A Shadid","year":"2022","unstructured":"Shadid A, Alobaida S, Binamer Y. Certolizumab to treat hidradenitis suppurativa. Dermatol Rep. 2022;15(2):9566.","journal-title":"Dermatol Rep."},{"issue":"12","key":"940_CR54","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1016\/j.jid.2021.04.026","volume":"141","author":"MDM Melendez-Gonzalez","year":"2021","unstructured":"Melendez-Gonzalez MDM, Hamad J, Sayed C. Golimumab for the treatment of hidradenitis suppurativa in patients with previous TNF-\u0152\u00b1 treatment failure. J Invest Dermatol. 2021;141(12):2975\u20139.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"940_CR55","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2018.06.046","volume":"80","author":"ARJV Vossen","year":"2019","unstructured":"Vossen ARJV, Doorn MBA, Zee HH, Prens EP. Apremilast for moderate hidradenitis suppurativa: results of a randomized controlled trial. J Am Acad Dermatol. 2019;80(1):80\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"940_CR56","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/bjd.21744","volume":"187","author":"HC Ring","year":"2022","unstructured":"Ring HC, Egeberg A, Zachariae C, Thomsen SF, Gyldenl\u00f8ve M. Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy. Br J Dermatol. 2022;187(5):813\u20135.","journal-title":"Br J Dermatol"},{"issue":"10","key":"940_CR57","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1111\/jdv.19252","volume":"37","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Podda M, Alavi A. Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: a phase 2 randomized study. J Eur Acad Dermatol Venereol. 2023;37(10):2098\u2013108.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"940_CR58","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s13555-023-00913-3","volume":"13","author":"AB Kimball","year":"2023","unstructured":"Kimball AB, Prens EP, Passeron T. Efficacy and safety of risankizumab for the treatment of hidradenitis suppurativa: a phase 2, randomized, placebo-controlled trial. Dermatol Ther (Heidelb). 2023;13(5):1099\u2013111.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"940_CR59","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaad.2019.05.065","volume":"82","author":"A Amir Ali","year":"2020","unstructured":"Amir Ali A, Seng EK, Alavi A, Lowes MA. Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: a systematic review. J Am Acad Dermatol. 2020;82(1):45\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"940_CR60","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1111\/ijd.16804","volume":"62","author":"I Lr","year":"2023","unstructured":"Lr I, Fb MD, Pp A, So A, Mp L. Azathioprine in hidradenitis suppurativa with inflammatory phenotype: a case series of 11 patients. Int J Dermatol. 2023;62(10):1300\u20133.","journal-title":"Int J Dermatol"},{"issue":"3","key":"940_CR61","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.ijwd.2020.02.007","volume":"6","author":"KT Savage","year":"2020","unstructured":"Savage KT, Brant EG, Rosales Santillan M, Morss PC, Salian P, Flood KS, et al. Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. Int J Womens Dermatol. 2020;6(3):159\u201363.","journal-title":"Int J Womens Dermatol."},{"issue":"4","key":"940_CR62","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamadermatol.2022.6266","volume":"159","author":"H Bui","year":"2023","unstructured":"Bui H, Bechara FG, George R. Surgical procedural definitions for hidradenitis suppurativa developed by Expert Delphi Consensus. JAMA Dermatol. 2023;159(4):441\u20137.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"940_CR63","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/jdv.19810","volume":"38","author":"PK Krajewski","year":"2024","unstructured":"Krajewski PK, Sanz-Motilva V, Flores Martinez S, Solera M, Ochando G, Jfri A, et al. Deroofing: a safe, effective and well-tolerated procedure in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2024;38(5):931\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Suppl 1","key":"940_CR64","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.jaad.2015.07.044","volume":"73","author":"A Mehdizadeh","year":"2015","unstructured":"Mehdizadeh A, Hazen PG, Bechara FG, Zwingerman N, Moazenzadeh M, Bashash M, et al. Recurrence of hidradenitis suppurativa after surgical management: a systematic review and meta-analysis. J Am Acad Dermatol. 2015;73(5 Suppl 1):S70-77.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"940_CR65","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.1582","volume":"6","author":"A Michelucci","year":"2023","unstructured":"Michelucci A, Janowska A, Granieri G, Margiotta FM, Morganti R, Romanelli M, et al. Advanced wound management approaches in hidradenitis suppurativa postsurgical lesions. Health Sci Rep. 2023;6(10): e1582.","journal-title":"Health Sci Rep."},{"issue":"11","key":"940_CR66","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jamasurg.2021.3655","volume":"156","author":"FG Bechara","year":"2021","unstructured":"Bechara FG, Podda M, Prens EP. Efficacy and safety of adalimumab in conjunction with surgery in moderate to severe hidradenitis suppurativa: the SHARPS randomized clinical trial. JAMA Surg. 2021;156(11):1001\u20139.","journal-title":"JAMA Surg"},{"issue":"6S","key":"940_CR67","doi-asserted-by":"publisher","first-page":"S22","DOI":"10.1016\/j.jaad.2024.09.007","volume":"91","author":"CB Dagenet","year":"2024","unstructured":"Dagenet CB, Lee KH, Fragoso NM, Shi VY. Approach to the patient with hidradenitis suppurativa: evaluating severity to guide therapy. J Am Acad Dermatol. 2024;91(6S):S22\u20136.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"940_CR68","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000005860","volume":"12","author":"A Krajewski","year":"2024","unstructured":"Krajewski A, Alsayed A, Capek A, Casey K, Chandawarkar R. Surgical management of hidradenitis suppurativa. Plast Reconstr Surg Glob Open. 2024;12(6): e5860.","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"940_CR69","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jdrv.2024.09.007","volume":"2","author":"M Zaino","year":"2024","unstructured":"Zaino M, McCampbell L, Baltes A, Schadt C, Callen J. Perioperative management of systemic immunomodulatory agents in patients receiving surgery for hidradenitis suppurativa. JAAD Rev. 2024;2:97\u20139.","journal-title":"JAAD Rev."},{"issue":"1","key":"940_CR70","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jaad.2020.09.039","volume":"85","author":"KT Savage","year":"2021","unstructured":"Savage KT, Singh V, Patel ZS. Pain management in hidradenitis suppurativa and a proposed treatment algorithm. J Am Acad Dermatol. 2021;85(1):187\u201399.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"940_CR71","doi-asserted-by":"publisher","first-page":"adv00471","DOI":"10.2340\/00015555-3830","volume":"101","author":"C Canard","year":"2021","unstructured":"Canard C, Diaz Cives A, Gaubil-Kaladjian I, Bertin E, Viguier M. Impact of bariatric surgery on hidradenitis suppurativa. Acta Derm Venereol. 2021;101(6):adv00471.","journal-title":"Acta Derm Venereol"},{"issue":"6","key":"940_CR72","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.surg.2019.12.015","volume":"167","author":"C Aboud","year":"2020","unstructured":"Aboud C, Zamaria N, Cannistr C. Treatment of hidradenitis suppurativa: surgery and yeast (Saccharomyces cerevisiae)-exclusion diet. Results after 6 years. Surgery. 2020;167(6):1012\u20135.","journal-title":"Surgery"},{"issue":"2","key":"940_CR73","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.jaad.2020.04.092","volume":"83","author":"E Molinelli","year":"2020","unstructured":"Molinelli E, Brisigotti V, Campanati A. Efficacy of oral zinc and nicotinamide as maintenance therapy for mild\/moderate hidradenitis suppurativa: a controlled retrospective clinical study. J Am Acad Dermatol. 2020;83(2):665\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"940_CR74","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.det.2024.12.011","volume":"43","author":"CB Dagenet","year":"2025","unstructured":"Dagenet CB, Gawey L, Hsiao JL, Shi VY. Lifestyle modifications and nonpharmacological treatments in hidradenitis suppurativa. Dermatol Clin. 2025;43(2):273\u201384. https:\/\/doi.org\/10.1016\/j.det.2024.12.011","journal-title":"Dermatol Clin"},{"issue":"2","key":"940_CR75","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/PRS.0b013e31821e6fb5","volume":"128","author":"L Highton","year":"2011","unstructured":"Highton L, Chan WY, Khwaja N, Laitung JKG. Treatment of hidradenitis suppurativa with intense pulsed light: a prospective study. Plast Reconstr Surg. 2011;128(2):459\u201366.","journal-title":"Plast Reconstr Surg"},{"issue":"8","key":"940_CR76","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/j.1524-4725.2009.01214.x","volume":"35","author":"E Tierney","year":"2009","unstructured":"Tierney E, Mahmoud BH, Hexsel C, Ozog D, Hamzavi I. Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser. Dermatol Surg. 2009;35(8):1188\u201398.","journal-title":"Dermatol Surg"},{"issue":"1","key":"940_CR77","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10103-013-1464-5","volume":"30","author":"D Koch","year":"2015","unstructured":"Koch D, Pratsou P, Szczecinska W, Lanigan S, Abdullah A. The diverse application of laser hair removal therapy: a tertiary laser unit\u2019s experience with less common indications and a literature overview. Lasers Med Sci. 2015;30(1):453\u201367.","journal-title":"Lasers Med Sci"},{"issue":"3","key":"940_CR78","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000518540","volume":"238","author":"M Schultheis","year":"2022","unstructured":"Schultheis M, Staubach P, Nikolakis G. LAight\u00ae Therapy significantly enhances treatment efficacy of 16 weeks of topical clindamycin solution in Hurley I and II hidradenitis suppurativa: results from period A of RELIEVE, a multicenter randomized, controlled trial. Dermatology. 2022;238(3):476\u201386.","journal-title":"Dermatology"},{"issue":"6","key":"940_CR79","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1159\/000524739","volume":"238","author":"M Schultheis","year":"2022","unstructured":"Schultheis M, Staubach P, Grabbe S. LAight\u00ae Therapy is an effective treatment option to maintain long-term remission of Hurley I and II hidradenitis suppurativa: results from period B of RELIEVE, a multicenter randomized, controlled trial. Dermatology. 2022;238(6):1092\u2013103.","journal-title":"Dermatology"},{"issue":"5","key":"940_CR80","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1080\/09546634.2019.1677842","volume":"32","author":"S Wilden","year":"2021","unstructured":"Wilden S, Friis M, Tuettenberg A. Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). J Dermatol Treat. 2021;32(5):530\u20137.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"940_CR81","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jaad.2021.10.060","volume":"87","author":"E Molinelli","year":"2022","unstructured":"Molinelli E, Sapigni C, Simonetti O, Brisigotti V, Giuliodori K, Offidani A. Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: a controlled prospective clinical study. J Am Acad Dermatol. 2022;87(3):674\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"940_CR82","first-page":"14115","volume":"13","author":"H Qu","year":"2021","unstructured":"Qu H, Gao L. Botulinum toxin type A for the management of hidradenitis suppurativa. Am J Transl Res. 2021;13(12):14115\u201320.","journal-title":"Am J Transl Res."},{"issue":"5","key":"940_CR83","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s40257-020-00537-9","volume":"21","author":"\u00d8 Grimstad","year":"2020","unstructured":"Grimstad \u00d8, Kvammen B\u00d8, Swartling C. Botulinum toxin type B for hidradenitis suppurativa: a randomised, double-blind, placebo-controlled pilot study. Am J Clin Dermatol. 2020;21(5):741\u20138.","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"940_CR84","doi-asserted-by":"publisher","first-page":"898","DOI":"10.12968\/jowc.2022.31.11.898","volume":"31","author":"S Moloney","year":"2022","unstructured":"Moloney S, Fitzgerald D, Roshan D, Gethin G. Impact of hidradenitis suppurativa-specific wound dressing system on patient quality of life and dressing-related pain: pilot study. J Wound Care. 2022;31(11):898\u2013906.","journal-title":"J Wound Care"},{"issue":"2","key":"940_CR85","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1111\/j.1742-481X.2008.00471.x","volume":"5","author":"PE Price","year":"2008","unstructured":"Price PE, Fagervik-Morton H, Mudge EJ, Beele H, Ruiz JC, Nystr\u00f8m TH, et al. Dressing-related pain in patients with chronic wounds: an international patient perspective. Int Wound J. 2008;5(2):159\u201371.","journal-title":"Int Wound J"},{"issue":"6","key":"940_CR86","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.jaad.2023.07.1037","volume":"89","author":"D Chopra","year":"2023","unstructured":"Chopra D, Anand N, Brito S. Wound care for patients with hidradenitis suppurativa: recommendations of an international panel of experts. J Am Acad Dermatol. 2023;89(6):1289\u201392.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"940_CR87","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/ijd.15124","volume":"60","author":"J Garelik","year":"2021","unstructured":"Garelik J, Babbush K, Ghias M, Cohen S. Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. Int J Dermatol. 2021;60(2):217\u201321.","journal-title":"Int J Dermatol"},{"issue":"4","key":"940_CR88","doi-asserted-by":"publisher","first-page":"e141","DOI":"10.1016\/j.jaad.2021.11.005","volume":"86","author":"FR Blum","year":"2022","unstructured":"Blum FR, Paci KM, Sayed CJ. Use of a punch biopsy tool as an alternative approach for incision and drainage of abscesses. J Am Acad Dermatol. 2022;86(4):e141\u2013e142. https:\/\/doi.org\/10.1016\/j.jaad.2021.11.005.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"940_CR89","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamadermatol.2019.0478","volume":"155","author":"HB Naik","year":"2019","unstructured":"Naik HB, Paul M, Cohen SR, Alavi A, Su\u00e0rez-Fari\u00f1as M, Lowes MA. Distribution of self-reported hidradenitis suppurativa age at onset. JAMA Dermatol. 2019;155(8):971\u20133.","journal-title":"JAMA Dermatol"},{"key":"940_CR90","volume":"18","author":"N Mastacouris","year":"2024","unstructured":"Mastacouris N, Midgette B, Strunk A, Garg A. Precocious puberty among children and adolescents with hidradenitis suppurativa. JAMA Dermatol. 2024;18: e243104.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"940_CR91","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2022-061049","volume":"151","author":"CH Cotton","year":"2023","unstructured":"Cotton CH, Chen SX, Hussain SH, Lara-Corrales I, Zaenglein AL. Hidradenitis suppurativa in pediatric patients. Pediatrics. 2023;151(5): e2022061049.","journal-title":"Pediatrics"},{"issue":"4","key":"940_CR92","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/pde.15331","volume":"40","author":"R Masson","year":"2023","unstructured":"Masson R, Parvathala N, Ma E, Shih T, Atluri S, Sayed CJ, et al. Efficacy of procedural treatments for pediatric hidradenitis suppurativa: a systematic review. Pediatr Dermatol. 2023;40(4):595\u2013605.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"940_CR93","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1111\/pde.15404","volume":"40","author":"R Masson","year":"2023","unstructured":"Masson R, Ma E, Parvathala N, Shih T, Atluri S, Hogeling M, et al. Efficacy of medical treatments for pediatric hidradenitis suppurativa: a systematic review. Pediatr Dermatol. 2023;40(5):775\u201388.","journal-title":"Pediatr Dermatol"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-025-00940-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-025-00940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:02:47Z","timestamp":1751619767000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-025-00940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,3]]},"references-count":93,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["940"],"URL":"https:\/\/doi.org\/10.1007\/s40257-025-00940-0","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,3]]},"assertion":[{"value":"13 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"V.Y.S. is on the board of directors for the Hidradenitis Suppurativa Foundation (HSF); is an advisor for the National Eczema Association; and is a stock shareholder of Learn Health and has served as an advisory board member, investigator, speaker, and\/or received research funding from Sanofi Genzyme, Regeneron, AbbVie, Genentech, Eli Lilly, Novartis, SUN Pharma, LEO Pharma, Pfizer, Incyte, Dermavant, Boehringer Ingelheim, Almirall, Alumis, Aristea Therapeutics, Menlo Therapeutics, Dermira, Burt\u2019s Bees, Galderma, Kiniksa, UCB, Ceraclere, Bain Capital, Target-PharmaSolutions, Castle Bioscience, Altus Lab\/cQuell, MYOR, Polyfins Technology, GpSkin, and Skin Actives Scientific. J.L.H. is on the board of directors for the Hidradenitis Suppurativa Foundation and has served as an advisor for AbbVie, Aclaris, Boehringer Ingelheim, Incyte, Novartis, Sanofi, UCB; as a speaker for AbbVie, Galderma, Novartis, Sanofi Regeneron, and UCB; and as an investigator for Amgen, Boehringer Ingelheim, and Incyte. C.J.S. reports being an investigator for AbbVie, ChemoCentryx, Incyte, InflaRx, Novartis, Astrazeneca, and UCB Pharma; received consultancy fees from AbbVie, Sanofi, Alumis, Astrazeneca, InflaRx, Sandoz, Incyte, Logical Images, Sonoma Biotherapeutics, and UCB Pharma; and is a speaker for AbbVie and Novartis. Authors K.H.L. and C.B.D. have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"IRB approval not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent to participate\/publish"}},{"value":"No new data were generated or analyzed in support of this research.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data\/code availability"}},{"value":"C.B.D.\u2014methodology, investigation, and writing\u2014original draft, review and editing; K.H.L.\u2014writing\u2014original draft, review and editing; C.S.\u2014supervision, conceptualization, methodology, and writing\u2014review and editing; J.L.H.\u2014supervision, conceptualization, methodology, and writing\u2014review and editing; V.Y.S.\u2014project administration, supervision, methodology, conceptualization, and writing\u2014review and editing.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}